Aspirin for the primary prevention of vascular and non-vascular outcomes

Citation

(2012), "Aspirin for the primary prevention of vascular and non-vascular outcomes", Clinical Governance: An International Journal, Vol. 17 No. 3. https://doi.org/10.1108/cgij.2012.24817caa.012

Aspirin for the primary prevention of vascular and non-vascular outcomes

Aspirin for the primary prevention of vascular and non-vascular outcomes

Article Type: Reviews of effectiveness From: Clinical Governance: An International Journal, Volume 17, Issue 3

Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Erqou, S., Sattar, N., Ray, K.K.,Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials,Archives of Internal Medicine,2012,doi:10.1001/archinternmed.2011.628

The authors concluded that aspirin as primary prevention reduced risk of non-fatal myocardial infarction, but not the risk of cardiovascular or cancer mortality; bleeding increased with aspirin. The authors’ conclusions reflect the evidence, but the limitations of the review should be borne in mind. Recommendations for further research seem appropriate.